Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) GF Value Rank: 7 (As of Aug. 19, 2026) — 75% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600211 Tibet Rhodiola Pharmaceutical Holding Co SHSE:600211
96 GF Score
Price ¥38.03
GF Value ¥38.86
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Tibet Rhodiola Pharmaceutical Holding Co GF Value Rank?

Tibet Rhodiola Pharmaceutical Holding Co SHSE:600211 -1.98% 96 GF Value Rank is 7 as of Aug. 19, 2026, which is 75% above its 10-year median of 4.00. GuruFocus rates SHSE:600211 with a GF Score™ of 96/100 and a GF Value™ of ¥38.86 (Fairly Valued). The stock has 3 warning signs investors should review.

Tibet Rhodiola Pharmaceutical Holding Co has the GF Value Rank of 7.

GF Value Rank evaluates the exclusive GuruFocus valuation and performance of a stock, rated on a scale from 1 to 10. It is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

A higher score indicates a stock with a relatively low valuation and substantial potential for outperformance. Conversely, a lower score often reflects stocks that are either highly overvalued or deeply undervalued, both of which tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


Tibet Rhodiola Pharmaceutical Holding Co GF Value Rank Related Terms


SHSE:600211 vs ZTS: GF Value Rank Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Tibet Rhodiola Pharmaceutical Holding Co's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tibet Rhodiola Pharmaceutical Holding Co GF Value Rank vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tibet Rhodiola Pharmaceutical Holding Co's GF Value Rank distribution charts can be found below:

* The bar in red indicates where Tibet Rhodiola Pharmaceutical Holding Co's GF Value Rank falls into.


SHSE:600211
96GF Score
Tibet Rhodiola Pharmaceutical Holding Co SHSE:600211
GF Value Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Value Rank →
What does a GF Value Rank of 7 mean?
Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) has a GF Value Rank of 7 as of Aug. 19, 2026. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Tibet Rhodiola Pharmaceutical Holding Co and its competitors. This is 75% above median its historical median of 4.00. Over the past decade, Tibet Rhodiola Pharmaceutical Holding Co's GF Value Rank has ranged from 1.00 to 10.00.
Is Tibet Rhodiola Pharmaceutical Holding Co's GF Value Rank too high?
Tibet Rhodiola Pharmaceutical Holding Co's current GF Value Rank of 7 is 75% above median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, Tibet Rhodiola Pharmaceutical Holding Co has a GF Score™ of 96/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Tibet Rhodiola Pharmaceutical Holding Co's GF Value Rank compare to ZTS?
Tibet Rhodiola Pharmaceutical Holding Co's GF Value Rank of 7 can be compared against companies in the Drug Manufacturers industry. Historically, Tibet Rhodiola Pharmaceutical Holding Co's own GF Value Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Value Rank for a Drug Manufacturers company?
A good GF Value Rank depends on the Drug Manufacturers industry context. However, GF Value Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Value Rank mean?
A high GF Value Rank can signal that a stock is expensive relative to its fundamentals. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Tibet Rhodiola Pharmaceutical Holding Co and its competitors. Tibet Rhodiola Pharmaceutical Holding Co's current GF Value Rank is 7, which is 75% above median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tibet Rhodiola Pharmaceutical Holding Co stock overvalued right now?
Based on GuruFocus' analysis, Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) is currently considered Fairly Valued. The stock's GF Value™ is ¥38.86, compared to a current price of ¥38.03 — trading 2.1% below its estimated fair value. The current GF Value Rank is 7, which is 75% above median its 10-year median of 4.00. Tibet Rhodiola Pharmaceutical Holding Co's overall GF Score™ is 96/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Value Rank calculated?
GF Value Rank is calculated from a company's financial statements. For Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211), the current GF Value Rank is 7 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) Overvalued in 2026?

Based on GuruFocus' analysis, Tibet Rhodiola Pharmaceutical Holding Co stock appears to be undervalued. The current stock price of ¥38.03 is trading 2.1% below its estimated GF Value™ of ¥38.86. GuruFocus considers Tibet Rhodiola Pharmaceutical Holding Co to be Fairly Valued.

Key valuation signals for SHSE:600211:

  • GF Value Rank: 7 (75% above median its 10-year median of 4.00)
  • GF Value™: ¥38.86 vs. price of ¥38.03 (2.1% below fair value)
  • GF Score™: 96/100 with 3 warning signs

No single metric tells the full story. See the SHSE:600211 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Tibet Rhodiola Pharmaceutical Holding Co Business Description

Address No. 3 Guangzhou Road, Area A, Lhasa Economic and Technological Development Zone, Tibet Autonomous Region, Lhasa, CHN, 850000
Tibet Rhodiola Pharmaceutical Holding Co is a pharmaceutical company engaged in the production and sales of capsules, biological agents, granules, and coatings. The company's products cover biopharmaceuticals, Tibetan medicine, traditional Chinese medicine, and chemical drugs, involving fields such as cardiovascular and cerebrovascular diseases, hepatobiliary diseases, orthopedic pain relief, rheumatism, and cold medicines.
96GF Score

Get the complete analysis for SHSE:600211

GF Value Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥38.03
Price
¥38.86
GF Value